RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. - Wikidata - wikimedia - TriplyDB

RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.

RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.

http://www.wikidata.org/entity/Q34870566

about

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Proteasome dysfunction in Drosophila signals to an Nrf2-dependent regulatory circuit aiming to restore proteostasis and prevent premature aging.Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma Data Analysis for High-Throughput RNAi Screening.Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.New strategies in the treatment of multiple myeloma.RNAi screening: new approaches, understandings, and organisms.Using functional genomics to overcome therapeutic resistance in hematological malignancies.At the Fulcrum in Health and Disease: Cdk5 and the Balancing Acts of Neuronal Structure and Physiology.An arrayed genome-scale lentiviral-enabled short hairpin RNA screen identifies lethal and rescuer gene candidates Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells.RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2.Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits.Multiple Myeloma: Treatment is Getting Individualized A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma.Inhibition of endothelial Cdk5 reduces tumor growth by promoting non-productive angiogenesis.Global cellular response to chemotherapy-induced apoptosis.Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.Fibroblast growth factor receptor 3 interacts with and activates TGFβ-activated kinase 1 tyrosine phosphorylation and NFκB signaling in multiple myeloma and bladder cancer.The isopeptidase inhibitor 2cPE triggers proteotoxic stress and ATM activation in chronic lymphocytic leukemia cells.Cyclin-dependent kinase 5 activity is required for allogeneic T-cell responses after hematopoietic cell transplantation in mice Kinase inhibitors as potential agents in the treatment of multiple myeloma.Future agents and treatment directions in multiple myeloma.Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.Novel investigational drugs active as single agents in multiple myeloma.Microenvironment drug resistance in multiple myeloma: emerging new players.Role of micro-RNAs in drug resistance of multiple myeloma.The impact of TEL-AML1 (ETV6-RUNX1) expression in precursor B cells and implications for leukaemia using three different genome-wide screening methods.A shRNA functional screen reveals Nme6 and Nme7 are crucial for embryonic stem cell renewal.Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome Bortezomib action in multiple myeloma: microRNA-mediated synergy (and miR-27a/CDK5 driven sensitivity)?Level of cdk5 expression predicts the survival of relapsed multiple myeloma patients Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.Loss of Cdk5 in breast cancer cells promotes ROS-mediated cell death through dysregulation of the mitochondrial permeability transition pore.Multiple myeloma: genome sequencing, drug development and the future outlook.Involvement of both caspase-8 and Noxa-activated pathways in endoplasmic reticulum stress-induced apoptosis in triple-negative breast tumor cells.Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome.

P2860

Q27004421-D1ABBC9B-B81F-408E-8C3E-BDE38D56917C Q28390091-2F9BBCFC-3EC0-4F1B-8174-15B61FEF8A16 Q28544663-96A03249-A944-458D-8A13-5D5B04DADDEC Q31125921-F9E01FE5-6A8F-45D6-8B9D-1D45FA97629F Q33418705-DA5E25EE-2AEE-4175-A1D8-031FE5945F2F Q33958520-DB9B315B-2452-4DAE-BA7B-C9B19F5CCF8F Q34033373-7E68C9C4-56B6-4CDA-AE9A-9F858E475BBB Q34401328-2F2AF5B9-30D4-4631-9E67-F287E229202B Q34418930-62FF4863-2012-4598-8B36-00753EE79B8C Q34496715-F09979F0-053E-47D9-93F1-76A497A24904 Q34612981-0DD376A3-B71C-47F9-A9F8-CA73A5288324 Q34974049-2FAB503A-DBD2-4801-84C8-BEA4042E6B78 Q36141927-4FC611B6-E97D-4204-B8EB-1F857F8BAEB5 Q36150369-301E8DC5-FCDB-4D42-90E6-5C2C217DFF52 Q36522964-E95F9711-1633-4049-AA52-1BF868B752B1 Q36763982-AC20B785-F462-4B4F-8617-37177F7E1AE4 Q36905854-8CDB973D-B090-4B30-8ACF-E2F2648E6890 Q37255788-AF00CAF5-B913-40EA-8AF8-CACE9B5A8D7C Q37277238-71FBB5D7-C988-4FAD-9493-57F6BAFAE8C2 Q37510049-23477A20-3BAC-4C09-9325-4B2755680D81 Q37564440-CC48FC94-386D-4BEA-9FE8-FC420F64F08A Q37585018-2F48429B-0022-4EE0-ABBD-1E309837CD67 Q37697253-961D5BBE-C658-4256-99C8-F4ED162F9829 Q38172300-C239E84B-B88C-4A97-A548-666EADE8CAEB Q38202977-51D6DD77-2908-4148-982A-04580424CFCC Q38324762-9D396509-A49E-4A59-A0FA-7A5499D53F7E Q38671390-F7D1DA9E-CAA1-4121-B1A2-B4B6DE052165 Q38690290-18F8D759-71C1-4CC5-A357-EE0AB7B11EB9 Q38913083-DE16E760-B74B-40FD-88D0-EC097CED405E Q38919670-B6203F32-10AC-4D89-8B35-403F8C372F07 Q39079942-1256AA10-4A6A-4129-ADBD-47074CAF4042 Q39296177-BF75A3A5-AF31-4F07-AAFA-522B3CBEB3D6 Q39432161-605DDEAD-3437-4E92-931E-4153D550E705 Q42322575-3A3D7D1B-7BE4-4923-9E93-0A9050F3D84C Q42357502-694D21BF-5B8D-4627-BE59-D79535C14B48 Q42762683-2751499F-538F-4AF2-B22D-58956C99AF37 Q48215901-2FF9A30B-051F-4FA6-818D-222D46047287 Q48378956-78567ABE-9341-4D41-B786-97FBB653BD7C Q49646749-128144BF-C3DC-4FAF-A6AC-D7149B6302AD Q49777578-EAF40CD6-DA0B-46EE-A1EC-C4792BE1443F

P2860

RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.

http://www.wikidata.org/entity/Q34870566

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

RNAi screen of the druggable g ...... ity in myeloma including CDK5.

@ast

RNAi screen of the druggable g ...... ity in myeloma including CDK5.

@en

RNAi screen of the druggable g ...... ity in myeloma including CDK5.

@nl

type

label

RNAi screen of the druggable g ...... ity in myeloma including CDK5.

@ast

RNAi screen of the druggable g ...... ity in myeloma including CDK5.

@en

RNAi screen of the druggable g ...... ity in myeloma including CDK5.

@nl

prefLabel

RNAi screen of the druggable g ...... ity in myeloma including CDK5.

@ast

RNAi screen of the druggable g ...... ity in myeloma including CDK5.

@en

RNAi screen of the druggable g ...... ity in myeloma including CDK5.

@nl

P1433

Q34870566-29D7FED8-1CBE-46AF-9361-7B157E2AC188

P1476

Q34870566-772B0DD8-17E9-42EF-8BA4-107D05B01E5A

P2093

Q34870566-138589A7-9648-4289-BCE1-CD2F12E6B73A

Q34870566-15AA89F8-FF0D-4AAC-99A6-F930BC6D9CD9

Q34870566-30422330-7C28-45F5-9F69-5D161ED28034

Q34870566-5D7CF3D0-622E-4519-BBD9-16BC157CD1B0

Q34870566-6552CAB3-E771-443C-9B53-73642BA50781

Q34870566-6C983C71-AA51-430D-A1C9-080E742E4A12

Q34870566-77ED7FF8-CE4C-4F3B-9D48-83E4225BE1F9

Q34870566-84960713-80F3-4447-BA3C-32E370B9B9BB

Q34870566-84A6C5DC-C761-4BC6-AD97-101CDAC414A7

Q34870566-9406E7DD-09F2-4FEE-88B5-436FB18BD28B

P2860

Q34870566-00B2BB32-5071-4035-95B9-98548D482C0D

Q34870566-0A729157-5F86-4155-BC27-EE36F1F39799

Q34870566-0E83EEBF-840F-4D9C-86A4-30448E9A34B7

Q34870566-1046CB04-F34C-4724-8F8A-EF588365B3D6

Q34870566-183B9BA5-CB86-44FC-86A9-FB253692B703

Q34870566-1A109126-E920-49A0-AB31-4E79B3E5FAB2

Q34870566-1BEFF20F-D9A9-4D7A-820F-397266323547

Q34870566-1BF40746-56BC-4B69-ABB6-029A42FC6384

Q34870566-208725C8-008B-411C-A579-3203AE0944E0

Q34870566-263F26B3-1BAF-4531-BA85-C6869A347490

P304

Q34870566-DC9CC9FC-AD30-48C2-83C8-BD750F778194

P31

Q34870566-1A9F4F9B-1FF9-466F-9A43-D66D4E588D6A

P356

Q34870566-54703A65-DF63-49AE-B450-1E9A84682C26

P407

Q34870566-A94082BF-9616-4E6A-9A41-B33983292286

P433

Q34870566-5BD204DB-B305-466F-84AE-9DA3CDE87B2E

P478

Q34870566-669070AD-F7B7-4BCD-BD3E-CFBBAF2A7319

P577

Q34870566-9132A715-06D4-4460-8139-8E9E4B744243

P698

Q34870566-A4B8F648-0F5D-4FBC-A85F-02D7041DD49F

P932

Q34870566-7AB1E882-3661-4310-BAEB-A70EA0CAD8FD

P356

BLOOD-2010-08-304022

P1433

P1476

RNAi screen of the druggable g ...... ity in myeloma including CDK5.

@en

P2093

A Keith Stewart

http://www.w3.org/2001/XMLSchema#string

Chang-Xin Shi

http://www.w3.org/2001/XMLSchema#string

Chris Sereduk

http://www.w3.org/2001/XMLSchema#string

Esteban Braggio

http://www.w3.org/2001/XMLSchema#string

Holly Yin

http://www.w3.org/2001/XMLSchema#string

Jessica E Schmidt

http://www.w3.org/2001/XMLSchema#string

Jonathan J Keats

http://www.w3.org/2001/XMLSchema#string

Laura A Bruins

http://www.w3.org/2001/XMLSchema#string

Rodger Tiedemann

http://www.w3.org/2001/XMLSchema#string

Spyro Mousses

http://www.w3.org/2001/XMLSchema#string

P2860

Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a proteasome-independent pathway

A model for p53-induced apoptosis

Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity

MDMX: a novel p53-binding protein with some functional properties of MDM2

How to activate p53

MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation

Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia

Stabilization and activation of p53 induced by Cdk5 contributes to neuronal cell death

p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment

Distinct roles for cyclin-dependent kinases in cell cycle control

P304

3847-3857

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-08-304022

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21289309

http://www.w3.org/2001/XMLSchema#string

P932

3083298

http://www.w3.org/2001/XMLSchema#string